Table 1 Baseline characteristics
No. of patients | Percent | |
|---|---|---|
Age, years | ||
Median (range) | 65 (19–84) | |
Sex | ||
Male | 72 | 77 |
Female | 21 | 23 |
ECOG performance status | ||
0 | 4 | 4 |
1 | 78 | 84 |
2 or higher | 11 | 12 |
Comorbid illness | ||
Any | 52 | |
Diabetes | 23 | |
Hypertension | 42 | |
Obstructive lung disease | 11 | |
Renal insufficiency | 3 | |
Histology | ||
Clear cell carcinoma (100 %) | 87 | 93 |
Mixed | 6 | 7 |
Time from diagnosis to treatment, months | ||
Median (range) | 14 (0–83) | |
Prior therapy | ||
Nephrectomy | 74 | 80 |
Cytokine immunotherapy | 9 | 10 |
Radiotherapy | 6 | 7 |
Laboratory findings (mean, SD) | ||
Hemoglobin, g/dL | 12.6 (2.0) | |
Corrected calcium, mg/dL | 9.3 (0.7) | |
Lactate dehydrogenase, U/L | 372 (243) | |
Number of metastatic site(s) | ||
Median (range) | 2 (1–5) | |
Sites of metastases | ||
Lung | 66 | |
Lymph nodes | 21 | |
Bone | 18 | |
Liver | 11 | |
Brain | 17 | |
MSKCC risk | ||
Favorable | 46 | 49 |
Intermediate | 36 | 39 |
Poor | 11 | 12 |
Heng score | ||
Favorable | 40 | 43 |
Intermediate | 38 | 40 |
Poor | 15 | 17 |